-
August 09, 2018 | Synspira’s PAAG Therapy Demonstrates Persistence Against Pseudomonas aeruginosa Persister Cells
Results published in Frontiers in Microbiology-Antimicrobials, Resistance and Chemotherapy
-
January 17, 2018 | Synspira’s Novel Glycopolymer Proves Effective Against Antibiotic Resistance
—Published study suggests that lead candidate SNSP113 may mitigate MRSA infections–
Synedgen Microbiologist Vidya Narayanaswamy led publication
-
January 03, 2018 | Synspira Announces $3 Million Development Award from Cystic Fibrosis Foundation
— Funding will support clinical development of SNSP113 —
Read More -
November 02, 2017 | Synspira Announces Data for Lead Candidate at the 31st Annual North American Cystic Fibrosis Conference
— Pre-clinical results demonstrate reduction in pulmonary inflammation and infection as well as mucus clearing by SNSP113 —
-
October 18, 2017 | Synspira Announces First Patient Dosed in Phase 1a Study of SNSP113 in Cystic Fibrosis
-
July 12, 2017 | Synspira’s Novel Glycopolymer Improves Effectiveness of Antibiotics Against Drug-resistant Bacteria Associated with Cystic Fibrosis
-
June 29, 2017 | Synspira Announces $8 Million in Funding and Board of Directors
Toggle navigation